PE20181016A1 - Compuestos antivirales de fosfodiamida de ester de beta aminoacido - Google Patents

Compuestos antivirales de fosfodiamida de ester de beta aminoacido

Info

Publication number
PE20181016A1
PE20181016A1 PE2018000216A PE2018000216A PE20181016A1 PE 20181016 A1 PE20181016 A1 PE 20181016A1 PE 2018000216 A PE2018000216 A PE 2018000216A PE 2018000216 A PE2018000216 A PE 2018000216A PE 20181016 A1 PE20181016 A1 PE 20181016A1
Authority
PE
Peru
Prior art keywords
amino
acid ester
amino acid
methylethoxy
methyl
Prior art date
Application number
PE2018000216A
Other languages
English (en)
Inventor
Petr Vachal
Izzat T Raheem
Zhiqiang Guo
Timothy John Hartingh
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56852398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20181016(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of PE20181016A1 publication Critical patent/PE20181016A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/16Esters of thiophosphoric acids or thiophosphorous acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion refiere un compuesto de formula I, en la que R1 y R2 se seleccionan cada uno independientemente entre H, -alquilo C1-C4, -CH2-fenilo, entre otros; R3 es -alquilo C1-C10 no sustituido, -CH2-fenilo no sustituido, arilo no sustituido, entre otros; RA es un resto de ester de L-aminoacido de formula i, un resto de ester de D-aminoacido de formula ii, entre otros; R4 es -alquilo C1-C4, -CH2-fenol, arilo; R9 es -alquilo C1-C10, -CH2-fenilo, arilo no sustituido, entre otros. Son compuestos favoritos: N-[(S)-{[(1R)-2-(6-amino-9H-purin-9-il)-1-metiletoxi]metil}{[(2S)-2-metil-3-(1-metiletoxi)-3-oxopropil]amino}fosforil]-L-alaninato 1-metiletilico; N-[(R)-{[(1R)-2-(6-amino-9H-purin-9-il)-1-metiletoxi]metil}{[(2S)-2-metil-3-(1-metiletoxi)-3-oxopropil]amino}fosforil]-L-alaninato 1-metiletilico, entre otros. La presente invencion tambien refiere a una composicion farmaceutica que comprende una cantidad eficaz de uno o mas agente antivirales del VIH como el abacavir, efavirenz, entre otros y un vehiculo farmaceuticamente aceptable. Es util para la inhibicion de la transcriptasa inversa del VIH tanto para su prevencion, tratamiento y la profilaxis y/o el retraso de la aparicion o de la progresion del SIDA y/o del ARC.
PE2018000216A 2015-08-10 2016-08-08 Compuestos antivirales de fosfodiamida de ester de beta aminoacido PE20181016A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562203265P 2015-08-10 2015-08-10

Publications (1)

Publication Number Publication Date
PE20181016A1 true PE20181016A1 (es) 2018-06-26

Family

ID=56852398

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000216A PE20181016A1 (es) 2015-08-10 2016-08-08 Compuestos antivirales de fosfodiamida de ester de beta aminoacido

Country Status (26)

Country Link
US (2) US9822138B2 (es)
EP (1) EP3334743B1 (es)
JP (2) JP6563585B2 (es)
KR (1) KR102163611B1 (es)
CN (1) CN107849071B (es)
AR (1) AR105643A1 (es)
AU (1) AU2016305941B2 (es)
CA (1) CA2994720C (es)
CL (1) CL2018000351A1 (es)
CO (1) CO2018001296A2 (es)
CR (1) CR20180092A (es)
EA (1) EA035028B1 (es)
EC (1) ECSP18018823A (es)
HK (1) HK1249107A1 (es)
IL (1) IL257156A (es)
MA (1) MA42615A (es)
MX (1) MX2018001729A (es)
MY (1) MY192607A (es)
NI (1) NI201800023A (es)
PE (1) PE20181016A1 (es)
PH (1) PH12018500292A1 (es)
SV (1) SV2018005629A (es)
TN (1) TN2018000048A1 (es)
TW (1) TWI639598B (es)
WO (1) WO2017027434A1 (es)
ZA (1) ZA201800514B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3285582B1 (en) * 2015-03-26 2020-11-11 Merck Sharp & Dohme Corp. Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors
WO2017100108A1 (en) * 2015-12-10 2017-06-15 Merck Sharp & Dohme Corp. Antiviral phosphodiamide prodrugs of tenofovir
US10450335B2 (en) 2015-12-15 2019-10-22 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
JP2017182110A (ja) * 2016-03-28 2017-10-05 セイコーエプソン株式会社 表示システム、表示装置、情報処理装置及び情報処理方法
US10449208B2 (en) 2016-08-25 2019-10-22 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
CN110023495A (zh) 2016-10-14 2019-07-16 精密生物科学公司 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶
US10736908B2 (en) 2016-10-26 2020-08-11 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
RU2759902C2 (ru) 2016-12-22 2021-11-18 Мерк Шарп И Доум Корп. Антивирусные алифатические сложноэфирные пролекарства тенофовира
AU2017378893A1 (en) 2016-12-22 2019-05-16 Idenix Pharmaceuticals Llc Antiviral benzyl-amine phosphodiamide compounds
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
JP7098748B2 (ja) 2017-12-20 2022-07-11 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. Stingアダプタータンパク質を活性化するホスホン酸結合を有する2’3’環状ジヌクレオチド
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ, インコーポレイテッド Hbv複製阻害剤としての置換ピロリジン化合物
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
EP3823629A4 (en) 2018-07-19 2022-05-04 Merck Sharp & Dohme Corp. PHOSPHINAMIDE PRODRUGS OF TENOFOVIR
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
BR112021002169A2 (pt) * 2018-08-09 2021-05-04 Glaxosmithkline Intellectual Property (No.2) Limited compostos úteis na terapia do hiv
CN108623632A (zh) * 2018-08-17 2018-10-09 上海麦步医药科技有限公司 一种替诺福韦艾拉酚胺的制备方法
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
PE20211655A1 (es) 2018-10-31 2021-08-24 Gilead Sciences Inc Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
KR20210137434A (ko) 2019-01-25 2021-11-17 브라운 유니버시티 연령 관련 염증 및 장애를 치료, 예방 또는 역전시키기 위한 조성물 및 방법
CA3129022C (en) 2019-03-07 2023-08-01 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
KR20210137518A (ko) 2019-03-07 2021-11-17 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
KR20220032568A (ko) 2019-06-25 2022-03-15 길리애드 사이언시즈, 인코포레이티드 Flt3l-fc 융합 단백질 및 사용 방법
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
CN117843811A (zh) 2019-09-30 2024-04-09 吉利德科学公司 Hbv疫苗和治疗hbv的方法
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CN116194144A (zh) 2020-08-07 2023-05-30 吉利德科学公司 膦酰胺核苷酸类似物的前药及其药物用途
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
KR20240006683A (ko) 2021-05-13 2024-01-15 길리애드 사이언시즈, 인코포레이티드 TLR8 조절 화합물과 항-HBV siRNA 치료제의 조합물
CA3222439A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359389A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
CA3222595A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
PL356525A1 (en) * 1999-12-22 2004-06-28 Metabasis Therapeutics, Inc. Novel bisamidate phosphonate prodrugs
CN100402539C (zh) 2000-07-21 2008-07-16 吉里德科学公司 核苷酸膦酸酯类似物前药及其筛选和制备方法
US7388002B2 (en) 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
PL2038290T3 (pl) * 2006-07-07 2014-03-31 Gilead Sciences Inc Modulatory receptora Toll-podobnego 7
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
JP2013523765A (ja) 2010-04-01 2013-06-17 イデニク プハルマセウティカルス,インコーポレイテッド ウイルス感染の治療のための化合物及び医薬組成物
WO2011140640A1 (en) 2010-05-11 2011-11-17 Simon Fraser University Selective glycosidase inhibitors and uses thereof
CA2843324A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
UY34262A (es) 2011-08-16 2013-04-05 Gilead Sciences Inc Hemifumarato de tenofovir alafenamida, sus composiciones, método de preparación, métodos para tratar infecciones virales y su uso para preparar medi camentos
ES2874774T3 (es) 2011-12-22 2021-11-05 Geron Corp Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
WO2017007701A1 (en) 2015-07-07 2017-01-12 Merck Sharp & Dohme Corp. Antiviral phosphodiamide compounds

Also Published As

Publication number Publication date
JP2019194200A (ja) 2019-11-07
IL257156A (en) 2018-03-29
HK1249107A1 (zh) 2018-10-26
ECSP18018823A (es) 2018-07-31
MX2018001729A (es) 2018-05-17
CL2018000351A1 (es) 2018-07-06
JP6563585B2 (ja) 2019-08-21
US20170044192A1 (en) 2017-02-16
CA2994720A1 (en) 2017-02-16
JP2018531216A (ja) 2018-10-25
KR20180030226A (ko) 2018-03-21
EA201890425A1 (ru) 2018-07-31
EP3334743A1 (en) 2018-06-20
CR20180092A (es) 2018-04-02
ZA201800514B (en) 2018-12-19
US9822138B2 (en) 2017-11-21
AU2016305941A1 (en) 2018-02-15
CO2018001296A2 (es) 2018-07-19
SV2018005629A (es) 2018-06-12
CN107849071A (zh) 2018-03-27
TN2018000048A1 (en) 2019-07-08
US20180065999A1 (en) 2018-03-08
MY192607A (en) 2022-08-29
EA035028B1 (ru) 2020-04-20
TWI639598B (zh) 2018-11-01
AU2016305941B2 (en) 2018-11-15
TW201712014A (zh) 2017-04-01
KR102163611B1 (ko) 2020-10-08
PH12018500292A1 (en) 2018-08-20
CA2994720C (en) 2020-11-03
WO2017027434A1 (en) 2017-02-16
MA42615A (fr) 2018-06-20
CN107849071B (zh) 2021-03-09
AR105643A1 (es) 2017-10-25
NI201800023A (es) 2018-06-12
EP3334743B1 (en) 2023-11-29

Similar Documents

Publication Publication Date Title
PE20181016A1 (es) Compuestos antivirales de fosfodiamida de ester de beta aminoacido
CO2018010748A2 (es) Agentes antivirales contra la hepatitis b
CO2019000069A2 (es) Agentes antivirales contra la hepatitis b
ECSP18083519A (es) Inhibidores de bromodominios
UY37997A (es) Agentes antivirales contra la hepatitis b
BR112015031763A2 (pt) Compostos, composição farmacêutica e processos para melhorar ou tratar infecção viral e para inibir a replicação de paramixovírus e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
TN2018000043A1 (en) Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
DOP2013000062A (es) Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas
CO2020002980A2 (es) Agentes antivirales contra la hepatitis b.
PE20170203A1 (es) Derivados de nucleosido sustituidos con 4'-difluorometilo como inhibidores de la replicacion de arn de la influeza
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112014028954A2 (pt) amidas de n-piridinila substituídas no anel como inibidores da quinase
BR112018011788A2 (pt) formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
GEP20237502B (en) B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
AR113803A1 (es) Compuesto de pirimidina como inhibidor de jak quinasas
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
NZ746906A (en) Oxaborole esters and uses thereof
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
CL2017002745A1 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
BR112022007488A2 (pt) Forma cristalina de base livre de um receptor c5a de componente do complemento
CL2021000844A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
EA201791807A1 (ru) Новый тритерпенон по с-3 с обратными амидными производными по с-17 в качестве ингибиторов вич
CO2017000443A2 (es) Derivados de 3h, 4h, 6h, 7h-piran[3,4-d]imidazol-4-ona activos como inhibidores de la aldosterona sintasa
MX2017010429A (es) Acido (2s,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxalilami no)-2-hidroximetil-2-metilpentanoico.